Morse Asset Management’s ADMA Biologics ADMA Stock Holding History

Morse Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$688K	Buy	76,394 +73,964	+3,044%	+$1.17M	0.14%	114
2025 Q4	$44.3K	Buy	+2,430	New	+$41K	0.01%	230
2025 Q3	–	Sell	-44,009	Closed	-$801K	–	370
2025 Q2	$801K	Buy	44,009 +35,309	+406%	+$720K	0.18%	99
2025 Q1	$173K	Buy	8,700 +1,400	+19%	+$24.2K	0.04%	149
2024 Q4	$125K	Buy	7,300 +7,075	+3,144%	+$133K	0.03%	170
2024 Q3	$4.5K	Buy	+225	New	+$3.5K	﹤0.01%	288

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morse Asset Management's ADMA Position: Q1 2026 in Review

Morse Asset Management increased its ADMA Biologics (ADMA) stake by 3,044% in Q1 2026, buying an estimated $1.17M and bringing the position to 76,394 shares worth $688K. The position accounts for 0.14% of the portfolio, ranked #114.

Morse Asset Management first reported a position in ADMA in Q3 2024 and has held it in 6 quarters since. The position peaked at $801K in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Morse Asset Management held 76,394 shares of ADMA Biologics worth $688K as of Q1 2026.
Morse Asset Management bought 73,964 ADMA Biologics shares in Q1 2026, an estimated $1.17M.
ADMA Biologics made up 0.14% of Morse Asset Management's portfolio in Q1 2026, its #114 holding.
Morse Asset Management first reported a position in ADMA Biologics in Q3 2024 and has held it in 6 quarters since.
Morse Asset Management's ADMA Biologics position peaked at $801K in Q2 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Morse Asset Management's 13F filing for Q1 2026, filed 14 May 2026.